These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 22237038)

  • 1. Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells.
    Pan JX; Ding K; Wang CY
    Chin J Cancer; 2012 Apr; 31(4):178-84. PubMed ID: 22237038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species.
    Jin Y; Lu Z; Ding K; Li J; Du X; Chen C; Sun X; Wu Y; Zhou J; Pan J
    Cancer Res; 2010 Mar; 70(6):2516-27. PubMed ID: 20215516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Antihelminthic Niclosamide Inhibits Cancer Stemness, Extracellular Matrix Remodeling, and Metastasis through Dysregulation of the Nuclear β-catenin/c-Myc axis in OSCC.
    Wang LH; Xu M; Fu LQ; Chen XY; Yang F
    Sci Rep; 2018 Aug; 8(1):12776. PubMed ID: 30143678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations.
    Osada T; Chen M; Yang XY; Spasojevic I; Vandeusen JB; Hsu D; Clary BM; Clay TM; Chen W; Morse MA; Lyerly HK
    Cancer Res; 2011 Jun; 71(12):4172-82. PubMed ID: 21531761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.
    Li Y; Li PK; Roberts MJ; Arend RC; Samant RS; Buchsbaum DJ
    Cancer Lett; 2014 Jul; 349(1):8-14. PubMed ID: 24732808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.
    Arend RC; Londoño-Joshi AI; Gangrade A; Katre AA; Kurpad C; Li Y; Samant RS; Li PK; Landen CN; Yang ES; Hidalgo B; Alvarez RD; Straughn JM; Forero A; Buchsbaum DJ
    Oncotarget; 2016 Dec; 7(52):86803-86815. PubMed ID: 27888804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling.
    Fonseca BD; Diering GH; Bidinosti MA; Dalal K; Alain T; Balgi AD; Forestieri R; Nodwell M; Rajadurai CV; Gunaratnam C; Tee AR; Duong F; Andersen RJ; Orlowski J; Numata M; Sonenberg N; Roberge M
    J Biol Chem; 2012 May; 287(21):17530-17545. PubMed ID: 22474287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular mechanisms of niclosamide antitumor activity].
    Moskaleva EY; Perevozchikova VG; Zhirnik AS; Severin SE
    Biomed Khim; 2015; 61(6):680-93. PubMed ID: 26716739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antihelmenthic phosphate niclosamide impedes renal fibrosis by inhibiting homeodomain-interacting protein kinase 2 expression.
    Chang X; Zhen X; Liu J; Ren X; Hu Z; Zhou Z; Zhu F; Ding K; Nie J
    Kidney Int; 2017 Sep; 92(3):612-624. PubMed ID: 28318631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway.
    Lu W; Lin C; Roberts MJ; Waud WR; Piazza GA; Li Y
    PLoS One; 2011; 6(12):e29290. PubMed ID: 22195040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.
    Arend RC; Londoño-Joshi AI; Samant RS; Li Y; Conner M; Hidalgo B; Alvarez RD; Landen CN; Straughn JM; Buchsbaum DJ
    Gynecol Oncol; 2014 Jul; 134(1):112-20. PubMed ID: 24736023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer.
    Gangrade A; Pathak V; Augelli-Szafran CE; Wei HX; Oliver P; Suto M; Buchsbaum DJ
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of niclosamide on basal-like breast cancers.
    Londoño-Joshi AI; Arend RC; Aristizabal L; Lu W; Samant RS; Metge BJ; Hidalgo B; Grizzle WE; Conner M; Forero-Torres A; Lobuglio AF; Li Y; Buchsbaum DJ
    Mol Cancer Ther; 2014 Apr; 13(4):800-11. PubMed ID: 24552774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer.
    Liu J; Chen X; Ward T; Mao Y; Bockhorn J; Liu X; Wang G; Pegram M; Shen K
    Int J Biochem Cell Biol; 2016 Feb; 71():12-23. PubMed ID: 26643609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma
    Zhou J; Jin B; Jin Y; Liu Y; Pan J
    Theranostics; 2017; 7(6):1447-1462. PubMed ID: 28529629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma Cells by Targeting Multiple Signal Pathways.
    Liao Z; Nan G; Yan Z; Zeng L; Deng Y; Ye J; Zhang Z; Qiao M; Li R; Denduluri S; Wang J; Wei Q; Geng N; Zhao L; Lu S; Wang X; Zhou G; Luu HH; Haydon RC; He TC; Wang Z
    Curr Cancer Drug Targets; 2015; 15(8):726-38. PubMed ID: 26118906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Niclosamide induces protein ubiquitination and inhibits multiple pro-survival signaling pathways in the human glioblastoma U-87 MG cell line.
    Cheng B; Morales LD; Zhang Y; Mito S; Tsin A
    PLoS One; 2017; 12(9):e0184324. PubMed ID: 28877265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer effects of niclosamide in human glioblastoma.
    Wieland A; Trageser D; Gogolok S; Reinartz R; Höfer H; Keller M; Leinhaas A; Schelle R; Normann S; Klaas L; Waha A; Koch P; Fimmers R; Pietsch T; Yachnis AT; Pincus DW; Steindler DA; Brüstle O; Simon M; Glas M; Scheffler B
    Clin Cancer Res; 2013 Aug; 19(15):4124-36. PubMed ID: 23908450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Wnt/β-catenin by anthelmintic drug niclosamide overcomes paclitaxel resistance in esophageal cancer.
    Wei W; Liu H; Yuan J; Yao Y
    Fundam Clin Pharmacol; 2021 Feb; 35(1):165-173. PubMed ID: 32579788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer.
    Sack U; Walther W; Scudiero D; Selby M; Kobelt D; Lemm M; Fichtner I; Schlag PM; Shoemaker RH; Stein U
    J Natl Cancer Inst; 2011 Jul; 103(13):1018-36. PubMed ID: 21685359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.